← All trials
NCT04193189
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2020
- Primary completion
- May 15, 2022
- Completion date
- May 15, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 634
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Dynavax Technologies CorporationCollaborator
- Cornell UniversityStudy chair
- University of CincinnatiStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.